Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | F7 | P08709 | 1/20 | 0.46 |
| ▸ | F3 | P13726 | 1/20 | 0.46 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.46 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.46 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29817984 | 1.00 | RECQL (0.50) | RECQLALDH1A1MAPK8NAPRTUSP2 | |
| Hydrochloric Acid SCHEMBL17906582 | 0.98 | RECQL (0.49) | RECQLALDH1A1MAPK8NAPRTUSP2 | |
| SCHEMBL28875207 | 0.87 | RECQL (0.47) | RECQLALDH1A1MAPK8NAPRTUSP2 | |
| SCHEMBL30839561 | 0.86 | ALDH1A1 (0.61) | RECQLALDH1A1MAPK8NAPRTUSP2 | |
| SCHEMBL5678627 | 0.86 | ALDH1A1 (0.61) | RECQLALDH1A1MAPK8NAPRTUSP2 | |
| SCHEMBL9622292 | 0.86 | ALDH1A1 (0.50) | RECQLALDH1A1NAPRTUSP2TBXAS1 | |
| SCHEMBL11875125 | 0.84 | ALDH1A1 (0.49) | ALDH1A1NAPRTUSP2TBXAS1HPGD | |
| SCHEMBL28875206 | 0.84 | NAPRT (0.45) | RECQLALDH1A1MAPK8NAPRTUSP2 | |
| SCHEMBL27175180 | 0.84 | TSHR (0.42) | ALDH1A1HPGDTSHRKDM4EMAPT | |
| SCHEMBL3647368 | 0.83 | RECQL (0.51) | RECQLALDH1A1MAPK8NAPRTUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103649087-B | Substituted imidazopyridine and intermediate thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-11-30 | — | — | CN | claimed |
| US-8242129-B2 | 6-phenylpyrimidinones as PIM modulators | EXELIXIS, INC. (US) | 2012-08-14 | — | — | US | claimed |
| EP-2459524-A2 | NOVEL COMPOUNDS AS MODULATORS OF GLUCOCORTICOID RECEPTORS | Cadila Healthcare Limited (IN) | 2012-06-06 | — | — | EP | claimed |
| WO-2011016050-A2 | NOVEL COMPOUNDS AS MODULATORS OF GLUCOCORTICOID RECEPTORS | CADILA HEALTHCARE LIMITED (IN) | 2011-02-10 | — | — | WO | claimed |
| US-20100135954-A1 | 6-Phenylpyrimidinones as PIM Modulators | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | claimed |
| EP-1928879-A2 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | Brystol-Myers Squibb Company (US) | 2008-06-11 | — | — | EP | claimed |
| WO-2007038314-A2 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-05 | — | — | WO | claimed |
| CN-115305097-A | Liquid crystal aligning agent, liquid crystal alignment film and method for producing same, liquid crystal element, liquid crystal display device, and polymer | JSR株式会社 | 2022-11-08 | — | — | CN | disclosed |
| CN-114381281-A | Liquid crystal aligning agent, liquid crystal alignment film, liquid crystal element, method for producing liquid crystal element, and compound | JSR株式会社 | 2022-04-22 | — | — | CN | disclosed |
| CN-114058382-A | Liquid crystal aligning agent, liquid crystal alignment film, and liquid crystal element | JSR株式会社 | 2022-02-18 | — | — | CN | disclosed |
| CN-114058381-A | Liquid crystal aligning agent, liquid crystal alignment film, and liquid crystal element | JSR株式会社 | 2022-02-18 | — | — | CN | disclosed |
| WO-2018144620-A9 | ANTI-FIBROTIC COMPOUNDS | CERTA THERAPEUTICS PTY LTD. (AU) | 2019-01-24 | — | — | WO | disclosed |
| WO-2018144620-A1 | ANTI-FIBROTIC COMPOUNDS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2018-08-09 | — | — | WO | disclosed |
| EP-2459524-A2 | NOVEL COMPOUNDS AS MODULATORS OF GLUCOCORTICOID RECEPTORS | Cadila Healthcare Limited (IN) | 2012-06-06 | — | — | EP | disclosed |
| WO-2012051117-A2 | SUBSTITUTED BENZAMIDES AND THEIR USES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-04-19 | — | — | WO | disclosed |
| WO-2011061527-A1 | COMBINATIONS COMPRISING A GLUCOCORTICOID RECEPTOR MODULATOR FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011016050-A2 | NOVEL COMPOUNDS AS MODULATORS OF GLUCOCORTICOID RECEPTORS | CADILA HEALTHCARE LIMITED (IN) | 2011-02-10 | — | — | WO | disclosed |
| EP-2234995-A1 | LEUKOTRIENE B4 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009077385-A1 | LEUKOTRIENE B4 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| EP-0373891-A2 | Anti-tumour agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100135954-A1 | 6-Phenylpyrimidinones as PIM Modulators | PIM1, PIM2, PIM3 | RECQL 2535/4885ALDH1A1 851/4885MAPK8 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.